ArticleKidney medicine2026
Alport Syndrome Family Screening and Management: Experience of a Tertiary Center.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Alport syndrome (AS) is one of the most common causes of inherited chronic kidney disease. Timely diagnosis and treatment of this condition can significantly influence its natural course. The evaluation of at-risk family members allows for the identification of new patients and the initiation of renoprotective measures that help prevent the progression of kidney disease. The aim of this study was to describe the implementation and results of cascade screening among at-risk relatives of a cohort of patients with AS followed at our unit. Study Design: This is a prospective, single-center study conducted at Nephrology Department, Health Local Unit Gaia/Espinho. We provided patients with letters intended for their first-degree relatives, highlighting the benefits of a referral for renal impairment assessment and genetic counseling. A total of 93 at-risk relatives underwent evaluation through biochemical testing (kidney function and urinalysis abnormalities) and were offered molecular screening for the familial Observations: Seventy-six (81.7%) at-risk relatives underwent molecular evaluation. A positive molecular test was achieved in 52 (68.4%) relatives, whereas the familial variant was excluded in 24 (31.6%) individuals. 9 (9.6%) individuals declined to proceed with screening and 8 (8.6%) experienced delay in obtaining their results. Among those with a positive molecular screening, 36.5% (n = 19) had urinary protein-creatinine ratio > 0.1 g/g creatinine and 13.5% (n = 7) had glomerular filtration rate (by the CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration] 2021 equation) < 60 mL/min/1.73 m Limitations: The relatively small size of this series from a single unit. The cascade screening based on a patient-led approach may not extent to all the at-risk relatives. Conclusions: Cascade screening of relatives of patients with AS is an effective strategy for identifying individuals with ongoing kidney disease or those at risk of future renal impairment. This approach enables the early initiation of nephroprotective measures and ensures timely access to appropriate genetic counseling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.